eriocitrin has been researched along with Diabetes Mellitus, Type 2 in 2 studies
*Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, CL; Guo, SJ; Jiang, B; Li, N; Li, XQ; Shi, DY; Wang, LJ | 1 |
| Chandra, S; Gangadhariah, M; Pardhi, T; Ravilla, J; Singh, SA | 1 |
1 review(s) available for eriocitrin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Molecular Docking Simulation; Structure-Activity Relationship | 2018 |
1 other study(ies) available for eriocitrin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Citrus nutraceutical eriocitrin and its metabolites are partial agonists of peroxisome proliferator-activated receptor gamma (PPARĪ³): a molecular docking and molecular dynamics study.
Topics: Citrus; Diabetes Mellitus, Type 2; Dietary Supplements; Flavonoids; Glucuronides; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; PPAR gamma | 2023 |